# NG Bio

> NG Bio is a VC fund in London backing Biotechnology and Therapeutics. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 2
- Last investment: Jan 2024
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/ngbioo
- Website: https://ngbio.co.uk

NG Bio is a therapeutic ventures that can change outcomes for patients with autoimmune and chronic inflammatory diseases.

## Contacts

5 contacts available for NG Bio. Shizune tracks 1 team members at NG Bio. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ng-bio?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Therapeutics | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Funding Round | 1 | 50% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jason Goldstein | Co-Founder | 1 | https://shizune.co/investors/profile/jason-goldstein-e132 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mesenbio | Mesenbio is a preclinical biopharmaceutical business based at the University of York. Its Cell Line Extracellular Vesicle Release (CLEVR) technique allows for a more diverse treatment pipeline by overcoming the most common hurdle in extracellular vesicle therapy. | $1.8M | Seed | Jan 09, 2024 |  |
| Bastion Therapeutics | Bastion Therapeutics is a preclinical stage biotechnology startup that uses proprietary platform technology to boost Tregs for the immune system | $840K |  | Sep 12, 2023 |  |

2 of 2 investments shown.

## Co-investors
- [Deep Science Ventures](https://shizune.co/investors/profile/deep-science-ventures) — VC Fund, 1 deal together
- [DSW Ventures](https://shizune.co/investors/profile/dow-schofield-watts-angels) — VC Fund, 1 deal together
- [Pioneer Group](https://shizune.co/investors/profile/pioneer-group-598a) — VC Fund, 1 deal together
- [Wren Capital](https://shizune.co/investors/profile/wren-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does NG Bio invest in?

NG Bio invests primarily in Biotechnology and Therapeutics startups, most often at Seed and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact NG Bio?

Public channels for NG Bio include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at NG Bio?

The team at NG Bio includes Jason Goldstein (Co-Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co